Clinical trials: Chemotherapy-induced Diarrhea
Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8
- Trial name
- NCT05296681
- Testing
- NBT-NM108
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Howard S. Hochster, MD
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Colon and Rectal Cancer
Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea
Chemotherapy-induced diarrhea (CID) is common in patients with gastrointestinal cancer. We evaluated whether the concentrated phytodietary compound (hereafter referred to as CPC) as a nutritional adjuvant to routine…
- Trial name
- NCT07460596
- Testing
- Concentrated Phytodietary Compound
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy-induced Diarrhea
A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects
The purpose of this study is to assess the safety and tolerability of orally administered SK10 powders in healthy adult subjects at three dose levels, following single and multiple doses.
- Trial name
- NCT06026397
- Testing
- SK10
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.
Chemotherapy-induced Diarrhea
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
- Trial name
- LARCID (NCT00582426)
- Testing
- Octreotide Long Acting Release, Standard Treatment
- Where
- 11 sites in Brazil
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Fissure in Ano, Diarrhea
The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure
Anal fissure define as a superficial tearing in mucosa on the anoderm surface distal to dentate line . The most important factor is hard stool passing with trauma to anal mucosa.
- Trial name
- NCT05091775
- Testing
- Asacol is used to treat and prevent mild to moderate acute fissure disease
- Where
- Iran
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Shiraz University of Medical Sciences
Diarrhea
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI…
- Trial name
- NCT01543451
- Testing
- Elsiglutide
- Where
- 21 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 138 people
- Sponsor
- Helsinn Healthcare SA
Diarrhea Caused by Drug (Disorder)
A Study of FT1 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of FT1 in participants aged 18 to 45 years. The main questions it aims to answer are: Is FT1 safe in healthy adults? Researchers will compare FT1 to a placebo (a…
- Trial name
- NCT06610487
- Testing
- FT1
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Neoplasms, Diarrhea
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Currently there is an ongoing clinical trial for patients with chemotherapy induced diarrhea. This trial is being conducted to evaluate the efficacy of two dose levels (30 mg and 40 mg) of an investigational drug in reducing the…
- Trial name
- NCT00050635
- Testing
- Sandostatin LAR Depot
- Where
- 34 sites in United States
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Diarrhea, Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Diarrhea is a relatively common complication in patients with cancer. At its inception, several mechanisms participated; malabsorption on the basis of mucositis induced by chemotherapy, dysbiosis induced by broad-spectrum…
- Trial name
- NCT02819960
- Testing
- Probio-Tec® BG-VCap-6.5
- Where
- Slovakia
- Volunteers
- 233 people
- Sponsor
- S&D Pharma SK s.r.o.
Gastric Cancer, Colorectal Cancer
E. Coli Nissle in Oncology
In patients with gastric or colorectal cancers, where a treatment with 5-Fluoruracil in combination with other chemotherapeutic remedies (FLO, FOLFOX, FOLFOX-Bev, FOLFIRI) is planned, it shall be investigated whether E.
- Trial name
- EcNO (NCT02706184)
- Testing
- E. coli Nissle suspension
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University of Hohenheim
Breast Cancer, Chemotherapy-induced Diarrhea
Probiotics for Abemaciclib-Induced Abdominal Discomfort.
This study aims to evaluate whether the addition of probiotics can help reduce abdominal discomfort (such as diarrhea) in breast cancer patients receiving Abemaciclib treatment.
- Trial name
- NCT07605728
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Leeuwenhoek Laboratories Co. Ltd.
Chemotherapy-induced Diarrhea
Inactivated Bacteroides Fragilis for Prevention of Chemotherapy-Induced Diarrhea
The incidence of chemotherapy-induced diarrhea (CID) is closely related to the types of anticancer drugs. Combination chemotherapy regimens such as fluorouracil derivatives and irinotecan, as well as tyrosine kinase inhibitors…
- Trial name
- NCT07309315
- Testing
- Inactivated Bacteroides fragilis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shenzhen Hospital of Southern Medical University
Malignant Tumor, Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Run-in safety study, to determine the safety of co-administration of irinotecan, raloxifene, and Xiao Chai Hu Tang (XCHT), and to optimize the blood collection time points for pharmacokinetic (PK) study for another randomized…
- Trial name
- NCT04926545
- Testing
- Xiao Chai Hu Tang (XCHT), Raloxifene, FOLFIRI regimen
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Diarrhea Caused by Drug (Disorder), Renal Cell Cancer
Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with metastatic renal cell carcinoma, and are commonly used as first-line option for this condition, but their use is encumbered by side effects, mainly…
- Trial name
- NCT04040712
- Testing
- Donor FMT
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Catholic University of the Sacred Heart
Oral Mucositis, Nausea
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial
RATIONALE: Polymerized (cross-linked) sucralfate malate paste (ProThelial) may be an effective single therapy approach for the management of chemoradiation mucositis, treating and preventing its occurrence in the oral cavity…
- Conditions
- Oral Mucositis, Nausea, Vomiting, Diarrhea
- Trial name
- NCT02016807
- Testing
- ProThelial
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Ashley Downs Bioscience
Breast Cancer
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment for HER2 positive locally advanced or metastatic breast cancer.
- Trial name
- HALT-D (NCT02910219)
- Testing
- Crofelemer
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Sandra Swain
Drug and/or Toxin-induced Diarrhea
Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
This is a randomized, stratified, double-blind, double-dummy, parallel group, placebo-controlled, dose finding, multicentre, multinational, phase II study in patient with colorectal cancer receiving 5- Fluorouracil (5-FU)-based…
- Trial name
- NCT02383810
- Testing
- Elsiglutide
- Where
- 54 sites in Belarus, Bulgaria and 6 more
- Volunteers
- 498 people
- Sponsor
- Helsinn Healthcare SA
Colorectal Cancer, Clostridioides Difficile Infection
L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal Cancer Patients
Colorectal cancer in periooperative period patients (n=60) will be enrolled to this study. Participants will be divided into 4 groups as follows: group 1 (n=15) will receive 2 capsules (per day) of L. plantarum 299v L.
- Conditions
- Colorectal Cancer, Clostridioides Difficile Infection, Diarrhea
- Trial name
- NCT06019312
- Testing
- Sanprobi IBS®
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Gdansk